Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lineage Cell Therapeutics, Inc. Common Stock
(NY:
LCTX
)
1.850
+0.010 (+0.54%)
Official Closing Price
Updated: 8:00 PM EST, Mar 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lineage Cell Therapeutics, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Lineage Cell Therapeutics (LCTX) Reports Q4 Revenue Beat and Narrowed Loss
↗
March 05, 2026
Via
Chartmill
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 05, 2026
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
February 26, 2026
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Issues Letter to Stockholders
January 05, 2026
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
A Peek at Lineage Cell Therapeutics's Future Earnings
↗
August 11, 2025
Via
Benzinga
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
January 06, 2026
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss
↗
November 06, 2025
Lineage Cell Therapeutics reports Q3 2025 results with a revenue beat but a wider net loss. The company advances its cell therapy pipeline and has cash into 2027.
Via
Chartmill
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
October 30, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 22, 2025
Via
Benzinga
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
September 08, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know
↗
August 27, 2025
Via
Benzinga
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
September 02, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
August 26, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
August 15, 2025
Via
Benzinga
Lineage Cell Revenue Doubles in Q2
↗
August 12, 2025
Via
The Motley Fool
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss
↗
August 12, 2025
Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027.
Via
Chartmill
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
August 05, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Two Biotech Stocks Poised For Big Moves On Monday
↗
June 23, 2025
Via
Benzinga
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
June 05, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
August 04, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
May 14, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
June 23, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook
↗
May 12, 2025
Via
Benzinga
Earnings Scheduled For May 13, 2025
↗
May 13, 2025
Via
Benzinga
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
May 12, 2025
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
